The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer with germline BRCA1 or BRCA2 mutations: SWOG S2001 NCT04548752.
 
Vincent Chung
Consulting or Advisory Role - Perthera
Research Funding - Merck (Inst)
 
Katherine Guthrie
No Relationships to Disclose
 
Michael Pishvaian
Stock and Other Ownership Interests - Perthera; Targeting Resistance in Cancer Cooperative; Tumor Board Tuesday
Consulting or Advisory Role - Astellas Pharma; Merck; Merus; Moderna Therapeutics; Pfizer; Renovo Rx; Seagen; Serna Bio; TriSalus Life Sciences
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Elevation Oncology (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); MEI Pharma (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Recursion Pharmaceuticals (Inst); Repare Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Perthera patient matching algorithm; Use patent for veliparib and FOLFOX
Travel, Accommodations, Expenses - Astellas Pharma; Merus; RenovoRx
 
Andrew Lowy
Honoraria - Kinnate Biopharma; Revolution Medicines; Silexion; Steba Biotech
Consulting or Advisory Role - Kinnate Biopharma; Steba Biotech
Research Funding - Takeda (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer
 
Davendra Sohal
Consulting or Advisory Role - AADi; AstraZeneca/MedImmune; Bayer; Elevar Therapeutics; Regeneron; Totus Medicines; TransThera Sciences (Nanjing), Inc.; Valar Labs
Speakers' Bureau - AstraZeneca; Incyte; Seagen
Research Funding - Ability Pharma (Inst); Amgen (Inst); Apexigen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bexion (Inst); Bristol-Myers Squibb (Inst); FibroGen (Inst); Genentech (Inst); Hengrui Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); NextCure (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Triumvira Immunologics, Inc (Inst)
Travel, Accommodations, Expenses - Ability Pharma
 
Kim Reiss
Honoraria - MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Carisma Therapeutics; Foundation Medicine; Guardant Health; Merus NV; MOMA Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology; GlaxoSmithKline (Inst); Lilly (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from invention (I)
Expert Testimony - Elmhurst Hospital; NYU School of Medicine
 
Nina Sanford
Honoraria - AstraZeneca; Signatera; Total Health Conferencing
 
Carmen Allegra
No Relationships to Disclose
 
Sarah Colby
No Relationships to Disclose
 
Eileen O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); Revolution Medicines; SERVIER (I); Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Revolution Medicines (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
E. Gabriela Chiorean
Consulting or Advisory Role - AADi; Astellas Pharma; BPGbio; Bristol-Myers Squibb/Celgene; IgM Biosciences; Ipsen; Merus; Pfizer; Purple Biotech; Regeneron; Takeda
Research Funding - Affini-T Therapeutics (Inst); BioAtla; Boehringer Ingelheim (Inst); Erasca, Inc (Inst); FibroGen (Inst); Genentech (Inst); Gilead/Forty Seven (Inst); Lonza (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Merus
 
Philip Philip
Honoraria - Astellas Pharma; Bayer; BioNTech SE; incyte; Ipsen; Novocure; Seagen; SERVIER; Taiho Pharmaceutical; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Incyte
Research Funding - Bayer (Inst); BioNTech SE (Inst); Genentech (Inst); halozyme (Inst); incyte (Inst); Lilly (Inst); Merck (Inst); merus (Inst); novartis (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals